Dyax Corp. Company Profile (NASDAQ:DYAX)

Analyst Ratings

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $37.00 (3.67% downside)

Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetActions
12/7/2015Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Jefferies GroupDowngradeBuy -> Hold$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015WedbushDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2015Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2015Bank of America Corp.Boost Price TargetBuy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/22/2016        
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.05)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313($0.05)($0.06)$14.80 million$13.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.03)($0.03)($0.03)
Q4 20162($0.01)$0.01$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
DateHeadline
07/27/16 09:26 PMHow Will Shire's ADHD Franchise Perform in 2Q16? - Market Realist
07/26/16 07:52 AMShire : ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia
07/21/16 07:13 AMEarnings Focus and Crowd Sourced Sentiment Review for Dyax Corp. (NASDAQ:DYAX) - TGP
07/20/16 07:11 AMDyax Corp. (NASDAQ:DYAX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 03:51 PMTrading Performance and Target Watch for Dyax Corp. (NASDAQ:DYAX) - Press Telegraph
07/17/16 03:26 PMBurlington Sends Mixed Signals - Banker & Tradesman
07/17/16 08:15 AMBurlington Sends Mixed Signals
07/15/16 10:57 AMCrowd Rating and Earnings Recap for Dyax Corp. (NASDAQ:DYAX) - Telanagana Press
07/14/16 03:22 PMThree Movers to Watch for: RSP Permian, Inc. (RSPP), ZIOPHARM Oncology, Inc. (ZIOP), Merrimack Pharmaceuticals ... - iStreetWire
07/14/16 03:22 PMShire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta - TheStreet.com
07/13/16 08:59 PMDyax Corp. (DYAX) Current Analyst Ratings - Fiscal Standard
07/13/16 07:57 AMDyax Corp. (NASDAQ:DYAX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/10/16 03:31 PMDrug-Induced Angioedema
07/08/16 03:43 PMDrug-Induced Angioedema - Medscape
07/06/16 03:48 PMGlobal Breast Cancer Monoclonal Antibodies Market 2016- Amgen, Biocad, Biocon, Celltrion Pharm, CuraGen ... - cHollywood News Portal (press release)
07/06/16 03:48 PMDyax Corp. (DYAX) Broker Price Targets For The Coming Week - Fiscal Standard
06/30/16 07:56 AMShire : Top-Line Results for Phase 2 Trial of SHP607
06/30/16 07:56 AMShire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
06/29/16 03:40 PMShire : Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD
06/28/16 08:35 AMEquity Research and Technical Review on Dyax Corp. (NASDAQ:DYAX) - Press Telegraph
06/23/16 08:45 PMKeryx Biopharmaceuticals Appoints Two New Board Members - GlobeNewswire (press release)
06/22/16 03:51 PMWhat Is Shire's Outlook for 2016? - Market Realist
06/21/16 08:25 AMKeryx Biopharmaceuticals Appoints Two New Board Members - Nasdaq
06/19/16 03:31 PMThis Weeks Broker Views For Dyax Corp. (DYAX) - Fiscal Standard
06/15/16 08:28 AMRecently Issued Stock Ratings For Dyax Corp. (DYAX) - Fiscal Standard
06/14/16 08:34 AMPfizer : Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
06/10/16 03:51 PMShire : Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
06/07/16 03:51 PMFitch Downgrades Baxalta to 'BBB'; Withdraws Ratings - Business Wire (press release)
06/06/16 03:36 PMDYAX CORP. (NASDAQ:DYAX) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:05 AMSigns of change: Shire finalizes acquisition of Baxalta
06/03/16 09:52 PMSigns of change: Shire finalizes acquisition of Baxalta - newtoncitizen
06/03/16 03:55 PMSigns of change: Shire finalizes acquisition of Baxalta - Rockdale Citizen
06/01/16 10:01 PMBroker Watchlist: Dyax Corp. (DYAX) - Share Trading News - Broker Watchlist: Dyax Corp. (DYAX)Share Trading News11/09/2015 – Dyax Corp. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 37 price target on the stock. 11/05/2015 – Dyax Corp. had its “hold” rating reiterated by analysts at Needham & Company. 11/02/2015 – Dyax ...
05/30/16 09:38 PMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - HNN - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...
05/30/16 09:38 PMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - HNN - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...
05/30/16 09:38 PMStock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX) - HNN - Stock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Dyax Corp. (NASDAQ:DYAX) to ...
05/30/16 09:38 PMStock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX) - HNN - Stock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Dyax Corp. (NASDAQ:DYAX) to ...
05/27/16 07:23 PMHC Stocks to Path: Celgene Corporation (NASDAQ:CELG), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release) - HC Stocks to Path: Celgene Corporation (NASDAQ:CELG), Shire PLC (ADR) (NASDAQ:SHPG)share market updates (press release)Completed acquisition of Dyax Corp. (“Dyax”) and enrollment on track for SHP643 (formerly DX2930) Phase 3 studies for the treatment of Hereditary Angioedema (“HAE”). Patent upheld for LIALDA (mesalamine) delayed release tablets by U.S. District Court ...and more »
05/24/16 12:10 AMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...and more »
05/24/16 12:10 AMEarnings Review and Stock Rundown for Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Dyax Corp. (NASDAQ:DYAX) to post ...and more »
05/18/16 07:00 PMLatest Analyst Ratings For Dyax Corp. (DYAX) - Share Trading News - Latest Analyst Ratings For Dyax Corp. (DYAX)Share Trading News11/09/2015 – Dyax Corp. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 37 price target on the stock. 11/05/2015 – Dyax Corp. had its “hold” rating reiterated by analysts at Needham & Company. 11/02/2015 – Dyax ...
05/17/16 11:11 AMShare Recap and Earnings Focus on Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Share Recap and Earnings Focus on Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Dyax Corp. (NASDAQ:DYAX) ...and more »
05/16/16 06:42 PMNext-generation Antibody Therapeutics Market will reach US$ 6761.1 Million by 2022 - Medgadget.com (blog) - Next-generation Antibody Therapeutics Market will reach US$ 6761.1 Million by 2022Medgadget.com (blog)Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics. Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., ...
05/11/16 07:43 PMConsensus Rating Review for Dyax Corp. (NASDAQ:DYAX) - B.O.D.Y Confidential - Consensus Rating Review for Dyax Corp. (NASDAQ:DYAX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of N/A on shares of Dyax Corp. (NASDAQ:DYAX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/11/16 12:38 AMGalena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update - GlobeNewswire (press release) - Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate UpdateGlobeNewswire (press release)Dr. Gray currently serves on the board of directors of several publicly traded biotechnology companies: Acadia Pharmaceuticals, TetraLogic, Inc., Juniper Pharmaceuticals, Senomyx, Inc. Previously, Dr. Gray also served on the boards of Dyax Corp., GTC ...
05/09/16 07:10 PMFinancial Services Market Daily: Berkshire Hathaway, American International Group, First Citizens BancShares Inc - Most recently, Campili served as the head of healthcare investment banking for Europe, Middle East, and Africa (EMEA), and holds the distinction of having worked on the industry’s largest deals, including the company’s purchase of Dyax Corp. and Shire ...
05/04/16 07:19 PMAverage Analyst Rating for Dyax Corp. (NASDAQ:DYAX) - B.O.D.Y Confidential - Average Analyst Rating for Dyax Corp. (NASDAQ:DYAX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of N/A on Dyax Corp. (NASDAQ:DYAX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 07:15 PMMario Gabelli Comments on Dyax Corp - Dyax Corp. (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for the ...
04/28/16 08:52 PMDyax Corp. (DYAX) Updated Broker Price Targets - Share Trading News - Dyax Corp. (DYAX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Dyax Corp. (DYAX). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
04/27/16 02:30 AMDyax Corp. (NASDAQ:DYAX) Share Rating Recap - B.O.D.Y Confidential - Dyax Corp. (NASDAQ:DYAX) Share Rating RecapB.O.D.Y ConfidentialShares of Dyax Corp. (NASDAQ:DYAX) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »

Social

About Dyax Corp.

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DYAX
  • CUSIP: 26746E10
Key Metrics:
  • Previous Close: $38.41
  • 50 Day Moving Average: $37.73
  • 200 Day Moving Average: $29.05
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-0.26 EPS
  • Next Year EPS Consensus Estimate: $-0.14 EPS
Additional Links:
Dyax Corp. (NASDAQ:DYAX) Chart for Friday, July, 29, 2016